Background: Due to the acuity and time-sensitive needs of their clinical condition, patients presenting with
I n 1996, regulations that allowed emergency and resuscitation research on devastating, life-threatening illness and injury were developed by the U.S. Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS). These federal regulations addressed potential areas of research for which the current treatment was unsatisfactory or unstudied and to proceed when their acute critical clinical condition left potential subjects unable to provide prospective informed consent. Prior to 1996, such potential subjects had been excluded from acute resuscitation and emergency research investigations, as the acuity of their clinical condition rendered them incapable of meaningful research decision making and the time-sensitive nature of the proposed investigational interventions often precluded meaningful prospective consent from legally authorized representatives (LARs).
Over the past 20 years the exception from informed consent (EFIC) regulations (21 CFR 50.24) 1 and waiver of informed consent (WIC) regulations (45 CFR 46.101) 2 have been available for use in these research scenarios. The EFIC regulations apply to research using FDA-regulated products (i.e., drug or device interventions), while the WIC regulations apply to research not regulated by the FDA (i.e., head-tohead randomized comparisons of standards of care). However, both sets of regulations are harmonized with regard to the criteria that needs to be met to proceed with a study using EFIC or WIC. The criteria for appropriate use of EFIC/WIC are listed in Table 1 .
A body of literature has emerged around the application of the EFIC and WIC regulations. This includes various reports describing the importance, goals, and meaning of the various regulatory requirements, including the logistics of required prestudy work (in particular, community consultation), community opinions regarding research without consent, and the use of surrogates in research decision making. [3] [4] [5] [6] Others have described the challenges and perceived burden added by these regulations when applied to research. 7, 8 Despite this growing body of literature on the application of EFIC and WIC, there has not been a robust review of how appropriately investigators are utilizing EFIC and WIC. Although it is assumed that justification for the use of EFIC or WIC has occurred at the level of the institutional review board (IRB), the IRB deliberations are not known to the general scientific community, many of whom may not be familiar with the EFIC or WIC requirements. It therefore falls upon the investigator to describe why the presented study qualified for EFIC or WIC. Communicating the justification for the use of these regulations and how the prestudy regulatory requirements were completed are important for the interpretation of the results of the clinical trial. This also will ensure that the scientific community is using EFIC and WIC in an appropriate and ethical manner, as these potential participants are particularly vulnerable due to their lack of autonomy caused by their acute devastating clinical condition.
The purposes of this study were to 1) review and describe the circumstances of the use of EFIC or WIC for research reported in the literature in the 20 years since the regulations have been available and 2) to determine whether the research as it is presented justifies why these regulations were applicable and whether appropriate prestudy regulatory requirements were described.
METHODS
This investigation is a review of published trials utilizing EFIC or WIC. To identify these studies we 3. Collection of valid scientific evidence is necessary to determine the safety and effectiveness of the intervention.
4. Obtaining informed consent is not feasible because the subjects are not able to give their informed consent as a result of their medical condition.
5. The intervention must be administered before consent can be obtained from the subject's legally authorized representative.
6. There is no reasonable way to identify prospectively individuals likely to become eligible for participation.
7. Participation in the research holds out the prospect of direct benefit to the subjects. After the studies were identified, each study was assigned a primary reviewer. Each reviewer is an emergency physician who has participated in, developed, and conducted trials with EFIC and WIC and is well versed in the regulatory requirements. All have additional formal training in clinical research trial development and management. One reviewer (MB) was involved in early discussions with the FDA when EFIC regulations were developed in 1996, 9 has been an advisor for many EFIC and WIC studies, and has studied the application of the EFIC regulations, in particular community consultation.
The primary reviewer for each study confirmed that the trial in fact utilized EFIC or WIC. If EFIC or WIC was utilized, studies were classified as 1) ongoing with no data available, 2) completed with no published data available, or 3) completed with published data available. The only information obtained from the studies that were ongoing with no data yet available was the pathology of interest under study. Otherwise, ongoing studies with no data available and completed studies with no data available were subsequently excluded from this review.
For all studies that were completed with publication data available, the primary reviewer undertook a full review of the manuscript, utilizing standardized methods for data collection research. 10 Data points of interest were selected a priori and all data were entered and managed using Research Electronic Data Capture (REDCap). 11 If other publications regarding the same study were available (i.e., a description of research methodology and implementation or community consultation event), these publications were also reviewed. However, our primary focus was on the principal publication that described study results.
Data points collected included the pathology under study, enrollment location(s), enrollment numbers (number of subjects screened, randomized, and included), patient demographics, postenrollment consent procedures, and interventions performed by the data monitoring committees. To determine whether EFIC or WIC was justified, we searched the text of each publication for reference to the criteria defined by the FDA and DHHS that must be met to justify use of these regulations (Table 1) . We also searched for mention of prestudy regulatory requirements of the following: 1) an investigational new drug or investigational device exemption application to the FDA when EFIC was applied, 2) community consultation, and 3) public disclosure. Although not specifically required by the federal regulations, 12 IRBs may require that opt out procedures are available during prestudy community consultation and public disclosure: we therefore also noted if opt out was described in the study.
To confirm the accuracy of collected data, all studies were reviewed by a second reviewer. Any discrepancies were mitigated in a consensus review with all three reviewers. All data were analyzed descriptively. All analyses were performed with Stata (Version 15, StataCorp).
RESULTS
Our search methods identified 45 studies eligible for inclusion. Of these 45 studies, there were 11 ongoing studies (with no data available), four completed studies (with no publications or other data available), and two that were not EFIC or WIC studies. This left 28 completed and published studies to be fully reviewed by the investigators.
Of the 28 completed studies, 24 (86%) were conducted using EFIC and four (14%) completed using WIC. The pathologies under study in the reviewed studies are presented in Table 2 . The 28 completed trials are presented in Table 3 . Table 4 describes the study population and settings for these studies. Enrollment most often occurred prehospital (17, 61%). While some studies included both adults and children, only two studies were performed in exclusively pediatric populations, one in the acute management of seizures 13 and one regarding use of vasopressin in pediatric cardiac arrest. 14 To determine the scope of patient involvement in EFIC and WIC trials, we sought to determine total numbers of patients combined (in all trials) screened, randomized, and enrolled (Table 4 ). The combined numbers include 172,557 (range = 78-37,889 per trial) screened, 65,271 (range = 10-26,148 per trial) randomized, and 63,947 (range = 10-26,148 per trial) enrolled. This total includes 283 pediatric participants in the two dedicated pediatric trials.
We identified that 10 of the studies (36%) were terminated by a data safety monitoring committee after interim analysis or other scheduled monitoring. Early termination occurred most often related to predetermined futility endpoints (7/10, 70%). Additional termination reasons included futility due to lack of accrual enrollment (2, 20%), and in one study (10%), termination occurred due to increased mortality in the treatment group. 15 Tables 5 and 6 depict the reporting rates for completing prestudy regulatory requirements and if the decision to utilize EFIC or WIC was explicitly justified in the text. Reporting the prestudy requirements and reporting justification for EFIC or WIC was conducted relatively infrequently in the main study publication; 13 (46%) primary publications mentioned at least one of the required criterion. The most frequently mentioned justification criterion was that the potential participant was in a "life-threatening situation" (10, 36%). We did, however, identify secondary publications by the same authorship groups to elaborate further on their methodology, which in some cases included details of the justification for use of EFIC or WIC; 11 (39%) investigators published additional methodology manuscripts, and among these 11 publications, seven of them (59%) report at least one criterion to justify the use of EFIC or WIC. Of note, some investigators justified EFIC or WIC because the study was emergency research. Since not all emergency research requires EFIC or WIC, these comments were not considered adequate justification.
Additional components of the EFIC and WIC regulations include notification of the participant (if capacity is recovered) or their LAR of their enrollment into the trial and seeking consent after an EFIC or WIC enrollment for continued study participation. Of the 28 trials, three (9%) of the studies indicated that they required consent for continued participation from the patient directly, and 22 (79%) indicated that consent was sought from a LAR or the patient. Six (22%) of the studies did not indicate whether postenrollment notification after EFIC or WIC occurred or if continued consent was ever sought from either the patient or LAR. When notification of the EFIC or WIC enrollment was made and/or consent for participation was reported by the investigators, only a small minority of participants or their legally authorized representatives (n = 359; less than 1% of all study EFIC/WIC enrollments) withdrew or did not provide consent for continued study participation.
DISCUSSION
The process required to satisfy the requirements for EFIC and WIC is rigorous and demands careful attention and consideration by investigators, sponsors, and IRBs. Over the past 20 years, these regulations have been applied relatively infrequently, as we only identified 24 EFIC studies over that time period with published results and four using a WIC. In fact, the majority of studies that have been published come from the same few research networks, such as the Neurologic Emergency Treatment Trials Network (NETT) and Resuscitation Outcomes Consortium (ROC). The specific details and criteria for implementation of the EFIC and WIC regulations may therefore be known only to a relatively small number of investigators and IRBs. Yet, the number of potential participants and actual subjects in EFIC and WIC studies (as indicated by the nearly 173,000 patients screened and nearly 64,000 subjects enrolled) is quite large. These studies are often published in high-profile journals with a large readership by the general clinical and scientific community; study results potentially have farreaching implications.
The EFIC and WIC regulations were specifically designed to allow research when potential participants lack research consent decision-making capacity and whose clinical condition requires time-sensitive intervention. The clinical conditions of patients eligible for enrollment in EFIC and WIC trials are devastating, Data are reported as n (%). EFIC = exception from informed consent; WIC = waiver of informed consent. life-threatening, and acute. Because of the ethically sensitive nature of performing research in critically ill or injured individuals who lack capacity (and therefore autonomy) to provide prospective informed consent, the context and rationale for performing research without consent requires careful consideration and specific explanation. While some investigators provided detailed explanations of the logistic prestudy requirements to implement EFIC and WIC, our study suggests that many published reports of EFIC and WIC studies do not routinely provide any explanation or provide only superficial explanations (i.e., " an emergent condition") of why EFIC was necessary to answer the question under study. Research that proceeds without prospective informed consent may be viewed as adding additional risks to an already vulnerable person, since the effectiveness of the proposed intervention has not yet been proven. It is essential to have an ethical research process in place to study these life-threatening and time-sensitive pathologies and also that the general scientific community understands how this process functions. Studies employing EFIC/WIC over the past 20 years have addressed pathologies for which current clinical management is unsatisfactory or understudied.
Despite these efforts, in some circumstances, such as traumatic brain injury, no new medical intervention has been developed for several decades, suggesting the need for intense future study. 16 It would likely be of benefit for future investigators to use prior EFIC/ WIC experience to understand in detail how these important gaps in clinical management can be studied in an ethical manner.
There are no standardized guidelines for investigators describing the use of EFIC or WIC when preparing a manuscript for peer-reviewed publication. Additionally, journals do not routinely request a description of EFIC or WIC justification and regulatory procedures when providing guidelines for authors. This lack of standardized guidance may explain the varied approach seen in description of the EFIC and WIC processes. We propose that in manuscripts submitted for peer review, authors describe the full justification of studies performed under EFIC and the prestudy regulatory requirements completed, with specific reference to how this process relates to the study question. The process for subject or LAR notification of study enrollment and continued participation in the study should also be described in the manuscript. Additionally, the study should characterize any postenrollment concerns that may arise from subjects or LARs and, if applicable, the number of enrolled (39) Data are reported as n (%). EFIC = exception from informed consent; IDE = investigational device exemption; IND = investigational new drug; IRB = institutional review board; WIC = waiver of informed consent. "Direct benefits to subject" 2 (7) 3 (27) "Not practically carried out without waiver" 3 (11) 3 (27) Data are reported as n (%). EFIC = exception from informed consent; LAR = legally authorized representative; WIC = waiver of informed consent. Data are reported as n (%) or total (range per study). EFIC = exception from informed consent; ICU = intensive care unit; LAR = legally authorized representative; OR = operating room; WIC = waiver of informed consent. *No standard definition was provided by investigators; most studies in this catagory were trauma related. †One study was weight based; youngest enrolled was 13.8 kg, and oldest subject was 102 years.
ACADEMIC EMERGENCY MEDICINE • October 2018, Vol. 25, No. 10 • www.aemj.org subjects or LARs refusing to provide consent for continued participation or elect to withdraw from the study. The establishment of EFIC and WIC 20 years ago has created a standard and ethical mechanism by which investigators can study questions and interventions in true emergent clinical states. The answers to these clinical questions are critical and ultimately can save many lives. The conditions and process by which EFIC and WIC are conducted should be routinely reported to the scientific community to not only educate, but also ensure that standards are met regarding study of vulnerable populations not able to provide prospective informed consent.
LIMITATIONS
We acknowledge that our search methods may have missed other published reports of EFIC and WIC studies. However, we believe that the studies presented here are representative published EFIC and WIC studies. We believe that our observations have value and likely describe the extent of the reporting of the requirements and justification of EFIC or WIC in the current literature.
We also acknowledge that the exact wording of each criterion was not always used in the publications reviewed here. To reduce personal bias and excessive latitude in key definitions, each study was reviewed by all three investigators and any discrepancies were discussed until consensus was achieved.
CONCLUSION
Since their implementation in 1996, the exception from informed consent/waiver of informed consent regulations have allowed progress in research aimed at determining optimal care for devastating life-threatening conditions. However, consistent and rigorous report of regulatory prestudy requirements and justification of the use of exception from informed consent/waiver of informed consent is lacking in clinical trial publications or on websites such as ClinicalTrials.gov. Since research without consent is an ethically sensitive issue and not widely understood, better justification of its needs within the presentation of the research itself may educate the general medical community and also reduce concerns about whether or not the regulations are being properly applied.
